$4.75
2.66% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US6406714005
Symbol
NEPH
Sector
Industry

Nephros Inc Stock price

$4.75
-0.56 10.55% 1M
+0.77 19.35% 6M
-0.13 2.66% YTD
+3.29 225.34% 1Y
+3.59 310.47% 3Y
-3.21 40.33% 5Y
+2.81 144.96% 10Y
+3.23 212.50% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.13 2.66%
ISIN
US6406714005
Symbol
NEPH
Sector
Industry

Key metrics

Basic
Market capitalization
$50.5m
Enterprise Value
$45.3m
Net debt
positive
Cash
$5.2m
Shares outstanding
10.6m
Valuation (TTM | estimate)
P/E
33.9 | 42.3
P/S
2.8 | 2.7
EV/Sales
2.5 | 2.4
EV/FCF
16.7
P/B
5.0
Financial Health
Equity Ratio
76.6%
Return on Equity
0.9%
ROCE
13.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$17.9m | $18.9m
EBITDA
$1.6m | -
EBIT
$1.4m | $1.2m
Net Income
$1.5m | $1.2m
Free Cash Flow
$2.7m
Growth (TTM | estimate)
Revenue
32.3% | 33.3%
EBITDA
313.2% | -
EBIT
250.5% | 11,970.0%
Net Income
259.1% | 1,600.0%
Free Cash Flow
225.4%
Margin (TTM | estimate)
Gross
63.2%
EBITDA
9.0% | -
EBIT
8.1%
Net
8.3% | 6.3%
Free Cash Flow
15.2%
More
EPS
$0.1
FCF per Share
$0.3
Short interest
0.0%
Employees
31
Rev per Employee
$460.0k
Show more

Is Nephros Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Nephros Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Nephros Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Nephros Inc forecast:

Buy
88%
Hold
13%

Financial data from Nephros Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
18 18
32% 32%
100%
- Direct Costs 6.59 6.59
25% 25%
37%
11 11
37% 37%
63%
- Selling and Administrative Expenses 8.52 8.52
4% 4%
48%
- Research and Development Expense 1.20 1.20
40% 40%
7%
1.62 1.62
313% 313%
9%
- Depreciation and Amortization 0.17 0.17
15% 15%
1%
EBIT (Operating Income) EBIT 1.45 1.45
251% 251%
8%
Net Profit 1.48 1.48
259% 259%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Nephros Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nephros Inc Stock News

Neutral
MCAP MediaWire
23 days ago
New initiative accelerates cross-industry engagement, expands educational reach to drive long-term growth in water quality solutions Takeaways: Nephros launched the Nephros Water Institute to formalize and expand its national leadership in water safety education. The institute provides evidence-based curricula, webinars, and tailored training for healthcare and water safety professionals.
Neutral
GlobeNewsWire
23 days ago
SOUTH ORANGE, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leader in point-of-use water filtration, today announced the launch of the Nephros Water Institute, a dedicated education initiative established to formalize the company's leadership in industry education.
Neutral
Seeking Alpha
about 2 months ago
Nephros, Inc. ( NEPH ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Kirin Smith Robert Banks - President, CEO & Director Judy Krandel - Chief Financial Officer Conference Call Participants Thomas McGovern Ralph Weil Nick Farwell Presentation Operator Good day, and welcome to the Nephros, Inc. Third Quarter 2025 Financial Results Conference Call. [Operator Instructions...
More Nephros Inc News

Company Profile

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Renal Products segment comprises of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.

Head office United States
CEO Robert Banks
Employees 31
Founded 1997
Website www.nephros.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today